Ubs Group Ag Galmed Pharmaceuticals Ltd. Transaction History

Ubs Group Ag

  • $397 Billion
  • Q1 2024

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$0.4 - $0.9 $6,850 - $15,412
-17,125 Reduced 79.9%
4,307 $1,000
Q4 2022

Feb 08, 2023
SELL
$0.29 - $0.59 $1,610 - $3,276
-5,554 Reduced 20.58%
21,432 $10,000
Q3 2022

Nov 10, 2022
BUY
$0.35 - $0.65 $7,322 - $13,599
20,922 Added 345.02%
26,986 $8,000
Q2 2022

Aug 10, 2022
BUY
$0.44 - $1.77 $2,668 - $10,733
6,064 New
6,064 $4,000
Q1 2022

May 16, 2022
SELL
$1.23 - $2.07 $7,817 - $13,156
-6,356 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$1.75 - $3.03 $10,843 - $18,773
6,196 Added 3872.5%
6,356 $12,000
Q3 2021

Nov 15, 2021
BUY
$2.41 - $3.33 $385 - $532
160 New
160 $0
Q2 2021

Aug 13, 2021
SELL
$2.24 - $3.9 $7,656 - $13,330
-3,418 Closed
0 $0
Q1 2021

May 12, 2021
SELL
$3.19 - $5.4 $21,982 - $37,211
-6,891 Reduced 66.84%
3,418 $12,000
Q4 2020

Feb 11, 2021
BUY
$3.06 - $4.17 $31,545 - $42,988
10,309 New
10,309 $32,000
Q3 2020

Nov 12, 2020
SELL
$3.46 - $5.69 $2,190 - $3,601
-633 Closed
0 $0
Q2 2020

Jul 31, 2020
SELL
$3.22 - $6.08 $9,231 - $17,431
-2,867 Reduced 81.91%
633 $3,000
Q1 2020

May 01, 2020
BUY
$3.3 - $6.84 $9,154 - $18,974
2,774 Added 382.09%
3,500 $12,000
Q4 2019

Feb 14, 2020
BUY
$3.61 - $6.75 $2,620 - $4,900
726 New
726 $4,000
Q3 2019

Nov 14, 2019
SELL
$4.62 - $7.11 $5,479 - $8,432
-1,186 Closed
0 $0
Q2 2019

Aug 14, 2019
BUY
$5.68 - $8.68 $6,736 - $10,294
1,186 New
1,186 $9,000
Q1 2019

May 14, 2019
SELL
$7.27 - $9.07 $4,165 - $5,197
-573 Closed
0 $0
Q4 2018

Feb 14, 2019
SELL
$6.59 - $14.47 $232,930 - $511,456
-35,346 Reduced 98.4%
573 $4,000
Q3 2018

Nov 14, 2018
BUY
$10.55 - $15.28 $1,487 - $2,154
141 Added 0.39%
35,919 $488,000
Q2 2018

Aug 14, 2018
SELL
$5.04 - $17.96 $21,278 - $75,827
-4,222 Reduced 10.56%
35,778 $426,000
Q1 2018

May 15, 2018
BUY
$5.12 - $11.77 $201,031 - $462,137
39,264 Added 5334.78%
40,000 $223,000
Q4 2017

Feb 14, 2018
BUY
$6.78 - $9.32 $4,990 - $6,859
736 New
736 $7,000
Q3 2017

Nov 14, 2017
SELL
$7.36 - $9.29 $56,752 - $71,635
-7,711 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
7,711
7,711 $48,000

About Galmed Pharmaceuticals Ltd.

GLMD Quotes by TradingView
  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $7.78M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email